Allergen for Grass Pollen Allergy is under clinical development by Roxall Medizin and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Allergen for Grass Pollen Allergy’s likelihood of approval (LoA) and phase transition for Grass Pollen Allergy took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Allergen for Grass Pollen Allergy Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Allergen for Grass Pollen Allergy overview

Allergen extract was under development for the treatment of grass pollen allergy. It is administered subcutaneously and sublingual route. The drug candidate is a cluster-allergoid extract of grasses and rye (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens such as Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior, Secale cereale. These allergen extracts are key contributors of allergic rhinitis and rhino-conjunctivitis.

Roxall Medizin overview

Roxall Medizin (Roxall) is a manufacturer and distributor of pharmaceutical products. The company develops products in allergology, immunology and emergency medicine fields. Its products include CLUSTO-Prick and Prixi. Its CLUSTO-Prick product operates as a medical device for in-vivo diagnostic of allergic diseases and provides automated system for skin prick tests. Roxall also provides pharmaceutical products for therapy of poisoning emergencies (antidotes). The company offers allergy services to the allergologically operating specialist and clinics. It also provides biologically and biochemically standardized allergen extracts for diagnosis and treatment. Roxall is headquartered in Oststeinbek, Germany

Quick View Allergen for Grass Pollen Allergy LOA Data

Report Segments
  • Innovator
Drug Name
  • Allergen for Grass Pollen Allergy
Administration Pathway
  • Subcutaneous
  • Sublingual
Therapeutic Areas
  • Immunology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.